- Email: [email protected]
Retraction notice to “3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis” [Bioorg. Med. Chem. 19 (2011) 5175–5182]
Bioorganic & Medicinal Chemistry 23 (2015) 272
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com/locate/bmc
Retraction notice
Retraction notice to ‘‘3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis’’ [Bioorg. Med. Chem. 19 (2011) 5175–5182] Junya Shirai, Minoru Nakamura, Naoki Tarui, Tadatoshi Hashimoto, Yoshinori Ikeura Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). The article has been retracted at the request of the authors. Subsequent to publication, it became clear to the authorship group that there was a serious mistake about the origin of the lead compound. The manuscript indicated that the lead compound was found from high-throughput screening of our chemical library.
DOI of original article: http://dx.doi.org/10.1016/j.bmc.2011.07.014 http://dx.doi.org/10.1016/j.bmc.2014.11.026 0968-0896/Ó 2014 Elsevier Ltd. All rights reserved.
However, it was revealed that the lead compound had been originally designed and synthesized aiming to get the biological activities by one of the authors. Furthermore, Dr. Yukimasa was omitted as an author, while in fact Dr. Yukimasa led the drug discovery research toward the hit compound. The authors concluded that these facts made the paper inappropriate and unfaithful, and therefore made the decision to retract.
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com/locate/bmc
Retraction notice
Retraction notice to ‘‘3-Benzhydryl-4-piperidones as novel neurokinin-1 receptor antagonists and their efficient synthesis’’ [Bioorg. Med. Chem. 19 (2011) 5175–5182] Junya Shirai, Minoru Nakamura, Naoki Tarui, Tadatoshi Hashimoto, Yoshinori Ikeura Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). The article has been retracted at the request of the authors. Subsequent to publication, it became clear to the authorship group that there was a serious mistake about the origin of the lead compound. The manuscript indicated that the lead compound was found from high-throughput screening of our chemical library.
DOI of original article: http://dx.doi.org/10.1016/j.bmc.2011.07.014 http://dx.doi.org/10.1016/j.bmc.2014.11.026 0968-0896/Ó 2014 Elsevier Ltd. All rights reserved.
However, it was revealed that the lead compound had been originally designed and synthesized aiming to get the biological activities by one of the authors. Furthermore, Dr. Yukimasa was omitted as an author, while in fact Dr. Yukimasa led the drug discovery research toward the hit compound. The authors concluded that these facts made the paper inappropriate and unfaithful, and therefore made the decision to retract.